- Home
- DRDB vs TTRX Comparison
DRDB vs TTRX Comparison
Compare DRDB & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRDB | TTRX |
|---|---|---|
| Founded | 2024 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 298.8M |
| IPO Year | 2024 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DRDB | TTRX |
|---|---|---|
| Price | $10.73 | $10.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 74.5K | ★ 90.8K |
| Earning Date | 01-01-0001 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $900.00 |
| P/E Ratio | $597.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $2.57 |
| 52 Week High | $10.76 | $16.45 |
Technical Indicators
Market Signals| Indicator | DRDB | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 39.39 |
| Support Level | $10.50 | $9.02 |
| Resistance Level | N/A | $10.72 |
| Average True Range (ATR) | 0.02 | 0.85 |
| MACD | -0.00 | -0.23 |
| Stochastic Oscillator | 80.00 | 9.94 |
Price Performance
Historical ComparisonAbout DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.